

ASX Announcement

Imugene appoints Paul Wright as Vice President CMC

Sydney, Australia, 04 October 2022: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce the appoint of Paul Wright as Vice President CMC (Chemistry, Manufacturing and Controls).

Mr Wright is an accomplished bioprocess development leader with over 25 years of experience in the fields of protein and virus production. His areas of expertise include monoclonal antibodies, bioconjugate vaccines, viral vectors, and oncolytic viruses, with experience spanning all phases of development. Prior to joining Imugene, he spent 21 years at Pfizer holding positions of increasing responsibility within the Global Manufacturing and Vaccine Research and Development organizations.

Most recently as Director of Bioprocess and Analytical and member of the Executive Leadership team within Cancer Vaccines and Immunotherapeutics, he led a team responsible for the process, analytical, and formulation development of cancer vaccine projects from pre-clinical to first-in-human study stage. His work included leading the successful process development, tech transfer, and clinical trial manufacture of Pfizer's vaccinia-based oncolytic virus (PF-07263689).

Mr Wright holds a Bachelor of Science with Honours, Cell and Molecular Biology from Anglia Ruskin University, Cambridge UK.

Imugene MD & CEO, Ms Leslie Chong said: "Paul brings extensive expertise in upstream and downstream process development for protein, viral vector, bioconjugate and oncolytic virus drug products. His depth of experience with a global pharma leader will be of great benefit to Imugene and we're looking forward to his contribution to our outstanding team."

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

**Investor Enquiries**

investor@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

View us on YouTube @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia